Entrada Therapeutics, Inc. (TRDA) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
TRDA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Entrada Therapeutics, Inc. (TRDA) trades at a price-to-earnings ratio of -2.0x, with a stock price of $6.83 and trailing twelve-month earnings per share of $-3.97.
The current P/E is 117% below its 5-year average of 11.5x. Over the past five years, TRDA's P/E has ranged from a low of 4.8x to a high of 22.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, TRDA trades at a 109% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, TRDA trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TRDA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TRDA Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $9.04 | $0.81 | 11.2x | -3% |
| FY2024 Q4 | $17.29 | $1.91 | 9.1x | -21% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $15.98 | $1.59 | 10.1x | -13% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $14.25 | $2.96 | 4.8x | -58% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $14.17 | $0.63 | 22.5x | +95% |
Average P/E for displayed period: 11.5x
See TRDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TRDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TRDA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTRDA — Frequently Asked Questions
Quick answers to the most common questions about buying TRDA stock.
Is TRDA stock overvalued or undervalued?
TRDA trades at -2.0x P/E, below its 5-year average of 11.5x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does TRDA's valuation compare to peers?
Entrada Therapeutics, Inc. P/E of -2.0x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is TRDA's PEG ratio?
TRDA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.